Epstein-Barr virus-associated post-transplantation lymphoproliferative disorder (EBV-PTLD) has been well described as a complication following allogeneic stem cell transplantation (SCT), but has only recently been reported after cord blood transplantation (CBT). 1, 2 Some of the known risk factors for PTLD in bone marrow transplantation are invariably present in CBT and can become contributing factors for PTLD: a relatively low dose of donor T cells, frequent donor-recipient human leukocyte antigen (HLA) disparity and use of antithymocyte globulin (ATG) during conditioning.
Conversely, potential advantages could be that nearly all neonatal donors are EBV negative, thus reducing the risk from transfer of EBV-infected lymphocytes within the graft, and a relatively reduced likelihood of severe acute and extensive chronic graft-versus-host disease (GVHD) is expected in CBT recipients.
Here we describe the development of early-onset EBV-PTLD in a patient, who underwent double unrelated CBT. We investigated the origin (donors versus recipient) of the lymphoid proliferation, in relation to the chimerism kinetics, and the EBV status of both recipient and two CB grafts.
A 31-year-old man was diagnosed with a non-Hodgkin's lymphoma in 2000 and was successfully treated with chemotherapy including autologous SCT. From 2005, he developed a progressive pancytopenia, and a diagnosis of therapy-related myelodysplastic syndrome with 7q deletion was made. In February 2006, he received a CBT using two unrelated 4/6 HLA-matched CB units, one from male and the other from female. The conditioning regimen included thiotepa, fludarabine, melphalan and rabbit ATG; GVHD prophylaxis consisted of cyclosporine A (CsA) and mycophenolate mofetil (MMF).
The infused nucleated cell doses were 1.72 Â 10 7 /kg recipient and 1.65 Â 10 7 /kg respectively; the CD34 þ and CD3 þ cell doses were not available for the male older unit and 0.68 Â 10 5 / kg and were 0.65 Â 10 7 /kg for the female one. EBV serologic testing of the patient before transplantation revealed negative VCA-IgM and positive VCA-IgG and EBNA antibody titers, indicating past infection.
Spontaneous platelet recovery to more than 20 Â 10 9 /l required 42 days, while neutrophil engraftment (ANC4 0.5 Â 10 9 /l) occurred on day þ 28; filgrastim was administered from day þ 2 until neutrophil recovery.
Complete haematologic and cytogenetic remission was achieved: 4 months after CBT, conventional chromosomal analysis and fluorescence in situ hybridization revealed a normal female karyotype in all cells examined, with the absence of the 7q deletion.
To quantify donors and recipient engraftment after transplantation, we used a PCR-based analysis of polymorphic short tandem repeat (STR) markers included in a commercially available system (Profiler Plus, Applied Biosystems, Los Angeles, CA, USA); detection of the fluorescently labelled PCR products was performed by capillary electrophoresis; the final calculation of chimerism percentage was based on the ratio of informative donors and patient bands.
A complete donor chimerism was documented at 3 weeks after transplantation. The values of the percentage of the dominant female unit were 72, 73, 84, 93, 96 and 100% respectively from bone marrow (BM) samples obtained on day þ 21 and at months 1, 3, 6, 9 and 12 post transplantation.
Post-transplantation course was not complicated by acute GVHD nor cytomegalovirus reactivation. While tapering CsA, around day þ 120, a moderate cutaneous chronic GVHD occurred, which responded to oral prednisone, but delayed the MMF tapering.
Nine months post transplantation, while receiving MMF 1 g/ day, the patient developed persistent diarrhoea and marked weight loss. No causative organisms were identified by serologic and cultural tests and no lymphadenopathy or hepatosplenomagaly were demonstrated by CT scan and ultrasonography.
BM examination revealed infiltration of lymphocytes (up to 50% of total nucleated cells) with heterogeneous morphology; B-lineage positivity without clonal restriction resulted by immunophenotype analysis.
In January 2007, the patient was admitted to the hospital and gastroscopy and colonoscopy were performed. Duodenal and ileocolic biopsies showed replacement by a diffuse, polymorphous infiltrate consisting of a mixture of plasma cells, immunoblasts, intermediate and large lymphoid cells, within a background of inflammatory cells; immunohistochemical stains confirmed the B-cell nature of the proliferation; PCR study for immunoglobulin heavy chain rearrangement identified the presence of a polyclonal B-cell population.
EBV status of the lymphoid proliferation was examined on tissue sections: the expression of EBV-associated antigens EBNA2 and LMP1 (latent membrane protein-1 and EBV nuclear antigen-2) was detected and PCR for the EBV genome performed on biopsy and concurrent BM samples resulted positive. These pathologic findings were consistent with a diagnosis of polymorphic-type EBV-PTLD. However, results from EBV serologic tests and quantitative PCR for EBV-DNA on peripheral blood were negative at the time of biopsy. Furthermore, repeat EBV serologies, even after blood and platelet transfusions, were negative for acute infection of the recipient, and EBV genome was not detected by real-time PCR at any time in patient's samples. Testing for EBV by real-time PCR was also performed on DNA samples from both CB units, and EBV-DNA was not detected (o10 viral copies per milliliter); EBV serology was not available for both the CB units and the mothers.
For determining the origin of the PTLD, PCR analysis for STR markers (Profiler Plus, AB) was performed on patient biopsy specimens and revealed 95% cells from donor (dominant female unit) and 5% cells of host origin.
The patient was managed by withdrawal of immunosuppression (MMF) and administration of rituximab, 375 mg/m 2 weekly once for four doses, with a significant resolution of signs and symptoms.
He was free of disease at the last follow-up, 12 months after CBT and 3 months after his diagnosis of PTLD.
Recently, EBV-viremia and PTLD have been reported by several studies as additional complications that contribute to the morbidity and mortality following CBT, but despite a theoretical increased risk of EBV-PTLD after CBT and the rapid increase in the number of CBT in recent years, only a few PTLDs have been reported.
Until 2004, a total of nine cases (only two adults) were described in the literature, and the cumulative incidence of EBV-PTLD was 2% at 2 years in a retrospective analysis of 272 myeloablative CBTs at two Institutions. [3] [4] [5] [6] [7] More recently, Brunstein et al. at the University of Minnesota investigated the incidence of EBV-related complications in 335 patients undergoing CBT and documented an overall rate of 4.5% (total 15 cases, with 5 adults) with an incidence of 3.3% in recipients of myeloablative transplantations, 7% for nonmyeloablative transplantations and up to 21% among the subset of patients who received also ATG, suggesting a significantly higher risk of EBV-related complications in recipients of a nonmyeloablative preparative regimen with ATG. 8 The lower incidence of EBV-viremia and PTLD reported in earlier series may, at least in part, be related to the recent introduction of effective and highly sensitive techniques for quantitative measurements of EBV load and sequential monitoring of EBV reactivation. 9 Today, in fact, the use of quantitative PCR for EBV-DNA has dramatically changed the diagnosis of PTLD, with patients now being frequently diagnosed at a very early stage of this complication; furthermore, a close monitoring for EBV allows pre-emptive therapy based on increasing levels of the EBV genome, before the onset of clinical manifestations of disease, especially in high-risk patients as CBT recipients with GVHD.
Rituximab seems to be a promising new approach that appears more effective in controlling viral proliferation and avoiding progression into EBV-PTLD once viremia is detected and less effective once EBV-PTLD is fully developed. 9 The diagnosis of EBV-PTLD in our patient was made by clinical manifestations and biopsy of involved tissue, but was, unfortunately, neither supported nor anticipated by detection of diagnostic levels of EBV genome in the peripheral blood, using real-time PCR.
PTLD arising after CBT shares many common features with the PTLD from BM and solid organ transplantation, such as extranodal involvement, EBV positivity and B-cell phenotype with monomorphic or polymorphic morphology; however, a notable difference exists between PTLD after allogeneic SCT, which are almost always of donor origin, and those after solid organ transplantation, generally from recipient B cells.
The origin of PTLD arising after CBT has been investigated in all few cases reported in literature, and polymorphic DNA analyses have indicated that the lymphoid proliferation is invariably of donor origin in patients achieving full donor engraftment and only patients with mixed chimerism or failed engraftment have been found to develop PTLD of host origin, as recently observed by Gong et al. 10 in two children. Another characteristic of PTLD after SCT is that it is almost invariably derived from the proliferation of EBV-infected B cells and nearly 100% of lesions are EBV-positive, whereas up to 15% of PTLD after solid organ transplantations is reported to be EBV negative and tends to occur later.
In all cases described after CBT, positivity for B-cell markers and EBV-associated antigens is a consistent finding, which has been confirmed pathologically, as biopsies of involved tissues revealed infiltration of B cells expressing EBER (EBV-encoded small RNAs) and/or EBNA2 and LMP1 and/or EBV-DNA.
This high frequency of EBV presence in PTLD post CBT, comparable with the EBV status seen in other types of SCT (BM and peripheral blood), confirms that EBV infection plays a major role in early-PTLD etiopathogenesis. Finally, the most salient point among EBV-PTLD arising after CBT is the portal of entry of the virus. In all but one report, to date, the EBV genome has not been detected in any tested sample of CB and all tested recipients have shown evidence of past EBV infection, being seropositive for EBV pre transplant.
We also evaluated the EBV status in CB samples, performing quantitative PCR to detect EBV viral load, and EBV-DNA was absent.
These results suggest that donor CB is not the source of EBV infection and the primary EBV infection must be transmitted to the engrafted donor cells by residual infected host cells, after reactivation of a prior latent infection, or via the frequent blood transfusions.
There is a unique report, by Haut et al., 5 where EBV-DNA was detected by quantitative PCR in the CB unit used for transplantation, at a level low but consistent with a previous EBV infection in latent phase.
At the pre-transplant evaluation, the recipient had no VCAIgM but low VCA-IgG antibodies, passively acquired from previous transfusions and unable to prevent the development of a fatal PTLD; the EBV status of the mother and EBV serology of the donor before transplant were not available.
So the study was inconclusive: in this exceptional case, the PTLD might be related to a potential transmission of EBV infection to the recipient by donor CB lymphocytes -and this could make it necessary to screen the donor CB for EBV before transplant -or alternatively by EBV-infected maternal lymphocytes or cell-free virus, contaminating placental blood at delivery. 
